Cel Human body tries to keep blood pressure as stable and constant as possible, so its instabilities are indicators of systemicproblems. Among 1 B people affected by hypertension, however, blood pressure monitoring is ineffective at least in 47% ofthem, leading to 9 M deaths/year globally. Current monitors for self blood pressure monitoring show main drawbacks: theyinterfere with daily activities, often lack of reliability and standards, and only allow to measure the blood pressureintermittently, so information on the blood pressure trend is not available. BP24 is a wearable medical device fornoninvasive, continuous and highly accurate blood pressure monitoring, specifically targeting patients with hypertension andinpatients. Vita Sentry’s proprietary core technology enables a unique approach that takes into account the vascular tone tocompute the value of BP, instead of simply estimating it from the measure of the blood flow. By detecting the diameter ofarteries and arterioles with an accuracy of 0.5 μm over a measurement range, BP24 is the unique wearable intended forhighly accurate -golden-standard comparable- BP monitoring. Therefore, not only it can be used by patients withhypertension, but in the future it will be used in patients undergoing surgeries – and the company’s efforts are directedtowards that objective. Vita Sentry’s technology is enabling: being vasodilation and vasoconstriction in a number ofphysiological processes, knowing the arteries and arteriole diameters will allow to measure the metabolic rate and the stresslevel of a person. While this is a long-term objective, going to the market with BP24 for self-monitoring of people withhypertension is the goal of the innovation project. During Phase 1 project the Company will assess the scale-upindustrialization plan, the trials needed to demonstrate the validity of the proposed solution and will evaluate a sound go-tomarketstrategy to ensure successful commercialization of the device. Dziedzina nauki medical and health scienceshealth scienceshealth care serviceseHealthnatural sciencescomputer and information sciencesinternetinternet of thingsmedical and health sciencesclinical medicinesurgerysocial scienceseconomics and businessbusiness and managementbusiness modelsmedical and health sciencesclinical medicinecardiologycardiovascular diseases Program(-y) H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT) Main Programme H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument Temat(-y) SMEInst-01-2016-2017 - Open Disruptive Innovation Scheme Zaproszenie do składania wniosków H2020-SMEInst-2016-2017 Zobacz inne projekty w ramach tego zaproszenia Szczegółowe działanie H2020-SMEINST-1-2016-2017 System finansowania SME-1 - SME instrument phase 1 Koordynator VITA-SENTRY LTD Wkład UE netto € 50 000,00 Adres 17 MOTZKIN STR. 4246017 NETANYA Izrael Zobacz na mapie MŚP Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant. Tak Rodzaj działalności Private for-profit entities (excluding Higher or Secondary Education Establishments) Linki Kontakt z organizacją Opens in new window Uczestnictwo w unijnych programach w zakresie badań i innowacji Opens in new window sieć współpracy HORIZON Opens in new window Koszt całkowity € 71 429,00